Trials / Recruiting
RecruitingNCT05473624
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 153 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-1167 | Participants will receive HRS-1167. |
Timeline
- Start date
- 2022-08-23
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2022-07-26
- Last updated
- 2025-04-15
Locations
20 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05473624. Inclusion in this directory is not an endorsement.